BAT and PMI Collaborate to Produce Cigarettes in Switzerland

BATPMI by 2FIRSTS.ai
Dec.04.2023
BAT and PMI Collaborate to Produce Cigarettes in Switzerland
Swiss media Le Temps reports that British American Tobacco's Swiss subsidiary has reached a production agreement with Philip Morris International.

Swiss media outlet Le Temps reported on December 1st that the Swiss subsidiary of British American Tobacco (BAT) has revealed a collaboration agreement with Philip Morris International (PMI). According to the agreement, PMI will produce cigarettes for BAT at their factory located in the western Swiss city of Neuchâtel.

 

In its statement, BAT pointed out that this agreement is specifically targeted towards the domestic market in Switzerland. Reports suggest that due to insufficient production capacity at BAT's factories in Switzerland to meet market demands, the company has opted to collaborate with a rival factory. This is a common practice in the world of multinational corporations.

 

British American Tobacco (BAT) has announced that only a portion of its production in Neuchâtel will be dedicated to the Swiss market, while the remaining output, as well as previously exported goods, will be handled by other factories within the BAT Group. As part of the agreement between the two tobacco giants, six new positions will be added to the Boncourt factory (BAT's Switzerland-based facility).

 

This summer, British American Tobacco Switzerland announced that they would not completely exit Boncourt's operations, but would continue to retain warehouses and a shipping department there, providing approximately 15 jobs. The company's headquarters will also remain in Jura canton. As of December 14th, 2022, when the closure of the factory was announced, it employed a total of 220 staff members.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Australia’s NSW Finds Lower Vaping Rates Among Teenagers Aged 14 to 17
Australia’s NSW Finds Lower Vaping Rates Among Teenagers Aged 14 to 17
A new report from Cancer Council’s Generation Vape research project shows that fewer teenagers in New South Wales are trying vaping after the state government introduced tougher vaping goods laws. Among surveyed NSW teenagers aged 14 to 17, the proportion who had tried vaping fell from 29.6% in April 2024 to 20.1% in October 2025.
Mar.17 by 2FIRSTS.ai
PMI U.S. to Invest About USD 50 Million in New Business Solutions Center in Tampa
PMI U.S. to Invest About USD 50 Million in New Business Solutions Center in Tampa
On March 17, PMI U.S. announced an investment of about USD 50 million in a new Business Solutions Center in Tampa, Florida. The center is expected to create about 180 direct and indirect high-skilled jobs and will consolidate business solutions, distribution operations and customer service into one hub.
Mar.18 by 2FIRSTS.ai
Texas college data show rapid shifts in top vaping brands, with Geek Bar/Vape surging by 2025
Texas college data show rapid shifts in top vaping brands, with Geek Bar/Vape surging by 2025
A short communication in Drug and Alcohol Dependence examined changes in the most commonly used nicotine vaping brands among Texas college students from 2023 to 2025. The study analyzed 6,049 students aged 18–25 who reported past-30-day nicotine vaping across three repeated cross-sectional spring surveys. The report found that use of Esco Bar, Elf Bar, JUUL, and Puff Bar declined from 2023 to 2025, while Geek Bar/Vape increased.
Feb.27 by 2FIRSTS.ai
U.S. Adult Smoking Rate Falls to Historic Single-Digit Low of 9.9%, Study Shows Shift in Nicotine Use Patterns
U.S. Adult Smoking Rate Falls to Historic Single-Digit Low of 9.9%, Study Shows Shift in Nicotine Use Patterns
A new study analyzing National Health Interview Survey data found that adult cigarette smoking in the United States declined to 9.9% in 2024, down from 10.8% in 2023. The findings, published in NEJM Evidence, represent a historic milestone in U.S. tobacco control efforts. Researchers noted that while cigarette smoking is decreasing, the prevalence of e-cigarette and cigar use remained largely unchanged, suggesting a shift in nicotine consumption rather than the elimination of tobacco use.
Market
Mar.20
Product | 25-second preheat and 2,250mAh battery: Heaven Gifts’ REJO launches new HNB device on Japanese and UK e-commerce platforms
Product | 25-second preheat and 2,250mAh battery: Heaven Gifts’ REJO launches new HNB device on Japanese and UK e-commerce platforms
REJO, Heaven Gifts’ heated tobacco (HNB) brand, has listed the REJO CUBE on its official website. The device features a magnetic modular design with a detachable battery and an OmniHeat™ 360° heating system, and is now available via e-commerce channels in Japan and the UK, priced at 6,980 yen (about $45) in Japan.
Mar.06 by 2FIRSTS.ai